© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 15, 1288-1294,
August 4, 1999
© 1999 Oxford University Press
REVIEW |
Chromatin Remodeling and Transcriptional Regulation
Affiliation of authors: Division of Molecular Oncology, Washington University School of Medicine, St. Louis, MO.
Correspondence to: Douglas C. Dean, Ph.D., Division of Molecular Oncology, Campus Box 8069, Washington University School of Medicine, 660 South Euclid Ave., St. Louis, MO 63110 (e-mail ddean{at}im.wustl.edu).
Extensive studies in the past few years have begun to demonstrate that chromosome structure plays a critical role in transcriptional regulation. Two highly conserved mechanisms for altering chromosome structure have been identified: 1) post-translational modification of histones and 2) adenosine triphosphate (ATP)-dependent chromosome remodeling. Acetylation of histone lysine residues has been known for three decades to be associated with transcriptional activation. Recent discoveries, however, show that a number of transcriptional regulators are histone acetylases or histone deacetylases. Specific DNA-binding transcription factors recruit histone acetylases and deacetylases to promoters to activate or repress transcription. These results strongly support the notion that histone acetylation and deacetylation play an important role in transcriptional regulation. Recent findings have also provided insight into the molecular mechanisms by which ATP-dependent chromosome-remodeling activities participate in transcriptional regulation. Furthermore, some ATP-dependent chromosome-remodeling activities have been shown to complex with histone deacetylases. In the complexes studied to date, the ATP-dependent chromosome-remodeling activity enhances the histone deacetylase activity. Therefore, the two mechanisms appear to work in concert to achieve precise control of transcription. Disruption of chromosome remodeling has been linked to a number of diseases, and a complete understanding of the complex chromosome-remodeling machinery may lead to the development of new therapies.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Zhang and L. M. Khachigian Injury-induced Platelet-derived Growth Factor Receptor-{alpha} Expression Mediated by Interleukin-1{beta} (IL-1{beta}) Release and Cooperative Transactivation by NF-{kappa}B and ATF-4: IL-1{beta} FACILITATES HDAC-1/2 DISSOCIATION FROM PROMOTER J. Biol. Chem., October 9, 2009; 284(41): 27933 - 27943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Chowdhary, R. A. Ali, W. Albig, D. Doenecke, and V. B Bajic Promoter modeling: the case study of mammalian histone promoters Bioinformatics, June 1, 2005; 21(11): 2623 - 2628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-H. Leu, H. H. Yeh, C.-C. Huang, Y.-C. Chuang, S. L. Su, and M.-C. Maa Participation of p97Eps8 in Src-mediated Transformation J. Biol. Chem., March 12, 2004; 279(11): 9875 - 9881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Plumb, P. W. Finn, R. J. Williams, M. J. Bandara, M. R. Romero, C. J. Watkins, N. B. La Thangue, and R. Brown Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 Mol. Cancer Ther., August 1, 2003; 2(8): 721 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Bandyopadhyay, N. A. Okan, E. Bales, L. Nascimento, P. A. Cole, and E. E. Medrano Down-Regulation of p300/CBP Histone Acetyltransferase Activates a Senescence Checkpoint in Human Melanocytes Cancer Res., November 1, 2002; 62(21): 6231 - 6239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Subramanian, S. Hasan, M. Rowe, M. Hottiger, R. Orre, and E. S. Robertson Epstein-Barr Virus Nuclear Antigen 3C and Prothymosin Alpha Interact with the p300 Transcriptional Coactivator at the CH1 and CH3/HAT Domains and Cooperate in Regulation of Transcription and Histone Acetylation J. Virol., April 16, 2002; 76(10): 4699 - 4708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Gore, L.-J. Weng, W. D. Figg, S. Zhai, R. C. Donehower, G. Dover, M. R. Grever, C. Griffin, L. B. Grochow, A. Hawkins, et al. Impact of Prolonged Infusions of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia Clin. Cancer Res., April 1, 2002; 8(4): 963 - 970. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Laribee and M. J. Klemsz Loss of PU.1 Expression Following Inhibition of Histone Deacetylases J. Immunol., November 1, 2001; 167(9): 5160 - 5166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Butler, Y. Webb, D. B. Agus, B. Higgins, T. R. Tolentino, M. C. Kutko, M. P. LaQuaglia, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, et al. Inhibition of Transformed Cell Growth and Induction of Cellular Differentiation by Pyroxamide, an Inhibitor of Histone Deacetylase Clin. Cancer Res., April 1, 2001; 7(4): 962 - 970. [Abstract] [Full Text]
|
|
|
|
|
|
X. Yang, A. T. Ferguson, S. J. Nass, D. L. Phillips, K. A. Butash, S. M. Wang, J. G. Herman, and N. E. Davidson Transcriptional Activation of Estrogen Receptor {{alpha}} in Human Breast Cancer Cells by Histone Deacetylase Inhibition Cancer Res., December 1, 2000; 60(24): 6890 - 6894. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. A. Postigo and D. C. Dean Independent Repressor Domains in ZEB Regulate Muscle and T-Cell Differentiation Mol. Cell. Biol., December 1, 1999; 19(12): 7961 - 7971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Jiang, L. Zhou, B. Breyer, T. Feng, H. Cheng, R. Haydon, A. Ishikawa, and T.-C. He Tetracycline-regulated Gene Expression Mediated by a Novel Chimeric Repressor That Recruits Histone Deacetylases in Mammalian Cells J. Biol. Chem., November 21, 2001; 276(48): 45168 - 45174. [Abstract] [Full Text] [PDF]
|
|